The efficacy of tocilizumab to patients with rheumatoid arthritis refractory to anti-TNF agents: the open trial

The efficacy of tocilizumab to patients with rheumatoid arthritis refractory to anti-TNF agents: the open trial - The efficacy of tocilizumab to RA patients refractory to anti-TNF agents

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001240

Enrollment

Registered

2008-07-10

Start date

2008-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Tocilizumab (8 mg/kg of body weight) is to be infused every 4 weeks for 3 years

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with 3.2 or more of DAS28-CRP 6 months after treatment with infliximab or etanercept are to be enrolled.

Exclusion criteria

Exclusion criteria: 1. pregnant women or women trying to get pregnant 2. patients with dementia 3. patients considered inappropriate judged by attending physicians

Design outcomes

Primary

Measure	Time frame
DAS28 to be evaluated every 6 months for 3 years	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026